Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.

Cite this paper

@article{Gounder2016PhaseIS, title={Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.}, author={Mrinal M. Gounder and Alona Zer and William D. Tap and Samer Salah and Mark Andrew Dickson and Abha A Gupta and Mary Louise Keohan and Herbert H F Loong and Sandra P. D'Angelo and Stephanie K Baker and Mercedes M. Condy and Kjirsten Nyquist-Schultz and Lanier Tanner and Joseph P. Erinjeri and Francis H Jasmine and Sharon Friedlander and Robert W. Carlson and Thaddeus John Unger and Jean-Richard Saint-Martin and Tami Rashal and Joel Ellis and Michael G. Kauffman and Sharon Shacham and Gary K. Schwartz and Albiruni Ryan Abdul Razak}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2016}, volume={34 26}, pages={3166-74} }